Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sai Life Sciences Limited (SAILIFE.NS)
INR1,229.70
+35.10 (+2.94%)
IN NSE Industrials Specialty Business Services
Address
L4- 01 & 02, SLN Terminus Survey 500032
Hyderabad, TG, IN
Hyderabad, TG, IN
CEO
Krishnam Raju Kanumuri
Website
sailife.com
IPO
2024-12-18
ISIN INE570L01029
Description
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR1,229.70
+35.10 (+2.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
670.2K
Beta
0.39
Float Shares
89.48M
Free Float %
42.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.46% | -4.01% | +10.28% | +15.27% | +22.03% | +18.40% | +43.38% | +40.46% | +40.46% | +40.46% | +40.46% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,229.70
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Specialty Business Services: +7.6%+29.3% ★ Q1'26: +10.4% (vs Q1'25)
-
EPS growth Specialty Business Services: +24.4%+90.8% ★
-
FCF margin FCF growth · Specialty Business Services: +27.6%+10.7% ★ Q1'26: -25.7% (vs Q1'25)
-
EBIT margin Specialty Business Services: +9.0%+21.2% ★ Q1'26: +21.8% (vs Q1'25)
-
ROIC Specialty Business Services: +7.8%+13.3% ★ Q1'26: +15.0% (vs Q1'25)
-
Share dilution Specialty Business Services: +0.4%+7.5%
-
Debt / EBITDA Net debt/EBITDA · Specialty Business Services: -0.21×0.46× Q1'26: 0.41× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 4 EPS Ana. |
Mar 2027 5 Rev. Ana. 4 EPS Ana. |
Mar 2028 6 Rev. Ana. 4 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
16.96B
est: 16.49B (+2.8%)
|
22.21B
22.13B – 22.35B
+34.7% YoY
|
26.31B
25.99B – 26.65B
+18.5% YoY
|
31.62B
31.10B – 33.46B
+20.2% YoY
|
35.92B
35.18B – 36.66B
+13.6% YoY
|
| EBITDA |
4.42B
est: 4.52B (-2.2%)
|
6.10B
6.07B – 6.13B
+34.7% YoY
|
7.22B
7.13B – 7.31B
+18.5% YoY
|
8.68B
8.53B – 9.18B
+20.2% YoY
|
9.86B
9.65B – 10.06B
+13.6% YoY
|
| EBIT |
3.04B
est: 3.22B (-5.7%)
|
4.34B
4.33B – 4.37B
+34.7% YoY
|
5.14B
5.08B – 5.21B
+18.5% YoY
|
6.18B
6.08B – 6.54B
+20.2% YoY
|
7.02B
6.88B – 7.17B
+13.6% YoY
|
| Net Income |
1.70B
est: 1.67B (+1.8%)
|
3.64B
3.55B – 3.74B
+118.1% YoY
|
4.16B
4.07B – 4.36B
+14.2% YoY
|
5.26B
5.07B – 5.70B
+26.3% YoY
|
5.57B
5.00B – 6.15B
+6.1% YoY
|
| SGA |
469.33M
est: 1.38B (-66.1%)
|
1.86B
1.86B – 1.88B
+34.7% YoY
|
2.21B
2.18B – 2.24B
+18.5% YoY
|
2.65B
2.61B – 2.81B
+20.2% YoY
|
3.01B
2.95B – 3.08B
+13.6% YoY
|
| EPS |
8.83
est: 7.87 (+12.2%)
|
16.92
16.70 – 17.61
+115.1% YoY
|
19.86
19.17 – 20.53
+17.3% YoY
|
24.93
23.85 – 26.85
+25.5% YoY
|
26.25
23.54 – 28.96
+5.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Ownership data is not available for this company yet.
Executive team
Top executives
EBIT / Employee
1.37M
Shares Outstanding
212.02M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Krishnam Raju Kanumuri | Chief Executive Officer, MD & Executive Director | 62M | male |
| Ranga Raju Kanumuri | Executive Chairman | 29M | — |
| John Pavey | Global Head of Process Research & Development | — | — |
| Marcellus Johannes Velterop | Chief Commercial Officer | — | male |
| Milind Shenvi | Senior Vice President of Medicinal Chemistry | — | male |
| Runa Karan | Company Secretary, Compliance Officer & Legal Head | — | female |
| Sauri Gudlavalleti | Head of Special Projects | — | male |
| Sidhartha Das | Senior Vice President & Head of Human Resources | — | male |
| Sivaramakrishnan Chittor | Chief Financial Officer & Whole Time Director | — | male |
| Dean David Edney | Senior Vice President and Global Head of Process Research & Development | — | — |
| Sriram Gopalakrishnan | Vice President of Corporate Communication | — | male |
| Hitesh Patel | Senior Vice President of Business Development | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SAILIFE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
